Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome

200736 citationsJournal Articlegold Open Access

Authors

Linda Mileshkin · University of Melbourne

Dirk Hönemann · Peter MacCallum Cancer Centre

Peter Gambell · Peter MacCallum Cancer Centre

M Trivett · Peter MacCallum Cancer Centre

Yoshihiro Hayakawa · Peter MacCallum Cancer Centre

Mark J. Smyth · University of Melbourne

Victoria Beshay

Abstract

Our findings support the suggestion that thalidomide has anti-angiogenic and immunomodulatory effects in myeloma. The preferred method for assessing angiogenesis is plasma VEGF levels and the assessment of CD57+ cells for patients with myeloma receiving novel immunomodulatory drugs should be further investigated.

Topics & Keywords

Multiple Myeloma Research and Treatments Cancer Treatment and Pharmacology Peptidase Inhibition and Analysis

Publication Details

Published in: Haematologica

Volume 92, Issue 8, pp. 1075-1082

DOI: 10.3324/haematol.11208

Field-Weighted Citation Impact: 2.03

Command Palette

Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome

Authors

Abstract

Topics & Keywords

Publication Details